GlobeNewswire: Endocyte, Inc. Contains the last 10 of 217 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:29:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/20/1670445/0/en/Endocyte-Stockholders-Approve-Merger-Agreement-with-Novartis-AG.html?f=22&fvtc=4&fvtv=12147Endocyte Stockholders Approve Merger Agreement with Novartis AG2018-12-20T14:25:00Z<![CDATA[WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.]]>https://www.globenewswire.com/news-release/2018/11/07/1647347/0/en/Endocyte-Provides-Third-Quarter-2018-Financial-Results-and-Operational-Update.html?f=22&fvtc=4&fvtv=12147Endocyte Provides Third Quarter 2018 Financial Results and Operational Update2018-11-07T21:01:00Z<![CDATA[Entered into agreement and plan of merger with Novartis AG for $2.1Billion]]>https://www.globenewswire.com/news-release/2018/10/18/1623094/0/en/Endocyte-Enters-Into-Agreement-to-be-Acquired-by-Novartis-AG-for-2-1-Billion.html?f=22&fvtc=4&fvtv=12147Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion2018-10-18T05:10:00Z<![CDATA[Novartis to acquire Endocyte for $24 per fully diluted share in cash]]>https://www.globenewswire.com/news-release/2018/09/27/1577149/0/en/Endocyte-to-Present-at-Two-Investor-Conferences-on-October-2nd.html?f=22&fvtc=4&fvtv=12147Endocyte to Present at Two Investor Conferences on October 2nd2018-09-27T12:01:00Z<![CDATA[WEST LAFAYETTE, Ind., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at two upcoming investor conferences in New York, NY, on Tuesday, October 2nd, 2018.]]>https://www.globenewswire.com/news-release/2018/09/14/1571287/0/en/Endocyte-Announces-Closing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12147Endocyte Announces Closing of Public Offering of Common Stock2018-09-14T20:01:00Z<![CDATA[WEST LAFAYETTE, Ind., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public offering of an aggregate of 10,878,379 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $18.50 per share. All shares of common stock sold in the offering were sold by Endocyte.]]>https://www.globenewswire.com/news-release/2018/09/11/1569462/0/en/Endocyte-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12147Endocyte Announces Pricing of Public Offering of Common Stock2018-09-11T23:53:18Z<![CDATA[WEST LAFAYETTE, Ind., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 9,459,460 shares of its common stock at a price to the public of $18.50 per share. In addition, Endocyte granted the underwriters a 30-day option to purchase up to an additional 1,418,919 shares of its common stock on the same terms and conditions. All shares of common stock sold in the offering are being sold by Endocyte. Endocyte expects to close the offering on or about September 14, 2018, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2018/09/10/1568845/0/en/Endocyte-Announces-175-0-Million-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12147Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock2018-09-10T20:15:00Z<![CDATA[WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell $175.0 million of its common stock in an underwritten registered public offering. In addition, Endocyte expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of its common stock on the same terms and conditions. All shares of common stock to be sold in the proposed offering will be sold by Endocyte. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2018/09/10/1568484/0/en/Endocyte-Announces-FDA-Acceptance-of-Radiographic-Progression-Free-Survival-rPFS-as-an-Alternative-Primary-Endpoint-of-the-VISION-Trial-in-Addition-to-Overall-Survival-OS.html?f=22&fvtc=4&fvtv=12147Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)2018-09-10T12:00:00Z<![CDATA[Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval]]>https://www.globenewswire.com/news-release/2018/08/29/1558230/0/en/Endocyte-to-Present-at-Wells-Fargo-Securities-2018-Healthcare-Conference.html?f=22&fvtc=4&fvtv=12147Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference2018-08-29T12:01:00Z<![CDATA[WEST LAFAYETTE, Ind., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, Sept. 5, at 3:00 p.m. EDT.]]>https://www.globenewswire.com/news-release/2018/08/28/1557945/0/en/UPDATE-Endocyte-Announces-Presentations-at-the-CAR-TCR-Summit-2018.html?f=22&fvtc=4&fvtv=12147UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 20182018-08-28T21:04:50Z<![CDATA[WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that data from the Company’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform will be presented at the CAR-TCR Summit 2018 being held from Sept. 4th - 7th, 2018 in Boston, MA.]]>